Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms.
D016915:AIDS Vaccines / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D002460:Cell Line; D002499:Centrifugation, Density Gradient; D004274:DNA, Recombinant / Q000235:genetics; D005260:Female; D015870:Gene Expression; D005814:Genes, Viral; D015488:HIV Antigens / Q000235:genetics* / Q000378:metabolism; D016333:HIV Protease / Q000235:genetics / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000648:ultrastructure; D006801:Humans; D008561:Membrane Fusion; D019444:Vaccines, DNA / Q000276:immunology / Q000378:metabolism; D014771:Virion / Q000502:physiology / Q000648:ultrastructure
D016915:AIDS Vaccines; D004274:DNA, Recombinant; D015488:HIV Antigens; D017320:HIV Protease Inhibitors; C482721:HIV-1 recombinant subtype CRF02 AG DNA vaccine; D019444:Vaccines, DNA; D016333:HIV Protease